Every year on 28 February, Rare Disease Day shines a spotlight on the more than 300 million people worldwide living with a rare condition. For many of them and their families, the journey is marked by delayed diagnoses, limited treatment options, and unequal access to care. The day is a reminder that raising awareness is not enough on its own – it must go hand in hand with collaboration, innovation, and concrete action to improve patients’ daily lives.
Enabling selfcare in rare conditions
At Ypsomed, our ambition is to simplify self-injection and enable people to manage their therapy with confidence. While each rare disease presents unique challenges, many require regular injections – often lifelong.
With platforms such as YpsoMate, we support pharmaceutical partners in delivering therapies for rare indications including myasthenia gravis, haemophilia, hereditary angioedema and polycythemia vera. Intuitive handling, reliability and patient-centric design are essential to empower users in their everyday lives.
Flexible platforms for individual needs
Rare diseases often require highly specific drug formulations and packaging solutions. Our UnoPen platform demonstrates how adaptable injection systems can meet these individual requirements.
By combining technical flexibility and customization for drug and therapy needs, we help bring innovative therapies to patients efficiently and reliably.
Advancing rare disease care
Ypsomed is well equipped to continue supporting patients with rare diseases through innovative platforms such as YpsoLoop and YpsoDot. In addition, our digital health solutions combine connected injection devices and comprehensive digital therapeutic management tools that enable a seamless, end‑to‑end therapy experience across the entire treatment journey.
Collaboration makes the difference
Although progress in research and treatment continues, significant gaps remain. Many people living with rare diseases still face uncertainty and barriers to adequate care.
This Rare Disease Day, we reaffirm our commitment to working closely with partners across the healthcare ecosystem. Together, we aim to improve access to innovative therapies and further strengthen patient autonomy through safe and simple self-injection solutions.
